News

Data: Revlimid Triple Combo Is Better as Myeloma Maintenance Therapy

In people with newly diagnosed multiple myeloma following a stem cell transplant, a triple-combination maintenance therapy — of Revlimid (lenalidomide), Kyprolis (carfilzomib) and dexamethasone — significantly extended the time to disease progression or death, by 49%, compared with Revlimid alone. That’s according to an interim analysis of…

Talquetamab for Advanced Multiple Myeloma Up for Approval in EU

Janssen Pharmaceuticals is seeking European Union approval for talquetamab, a subcutaneous (under-the-skin) antibody therapy for hard-to-treat multiple myeloma. The request, in the form of a marketing authorization application to the European Medicines Agency (EMA), will be reviewed under accelerated assessment, which reduces the expected review period from…

International Myeloma Foundation Wins 2022 AWS IMAGINE Grant

The International Myeloma Foundation (IMF) is one of the nonprofit organizations awarded the 2022 Amazon Web Services (AWS) IMAGINE Grant, which was established to help harness technology for patients’ needs. IMF was a winner in the Momentum to Modernize category, wherein its efforts to use cloud technology to educate…

SP-3164 ‘Molecular Glue’ Stops Growth In Lab-grown Cells, Mice

SP-3164, an investigational small molecule protein degrader, showed potential for improved anti-multiple myeloma activity over similar approved compounds. That’s according to preclinical data from its developer Salarius Pharmaceuticals that showed SP-3164 triggered the death of lab-grown cancer cells and held back cancer growth in a mouse model of…

Dual FasTCAR T-Cell Therapy Effective Against Multiple Myeloma

GC012F, Gracell Biotechnologies’ investigational dual FastCAR T-cell therapy, was safe and highly effective at eradicating cancer cells in people with high-risk, newly diagnosed multiple myeloma, according to preliminary findings from an ongoing Phase 1 trial. “We are thrilled to report that BCMA/CD19 dual targeting FasTCAR-T GC012F is showing…

Real-world Study Supports Blenrep for Hard-to-treat RRMM

The efficacy and safety of Blenrep (belantamab mafodotin) as a treatment for relapsed/refractory multiple myeloma (RRMM) in a real-world setting is similar to what has been reported in clinical trials, according to a study from Israel. “Response rate, duration of response and toxicity profile appear to be comparable to…